Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections
1 December 2021
| Su Young
|
Retina / Uvea / Vitreous
|
IVI, In-house compounded, bevacizumab, compounding pharmacy, endophthalmitis
This multicentre study examining a five-year period from 2014 to 2018 evaluated the incidence rate and outcomes of endophthalmitis after intravitreal injection of in-house compounded bevacizumab. In-house compounded syringes were prepared in compounding pharmacy using sterile standard operating guidelines. All...